Cerus Corporation (CERS)
-NasdaqGM 5.12 
0.12(2.29%) 4:00PM EDT|After Hours
:
5.12 0.00 (0.00%) 4:37PM EDT
| Prev Close: | 5.24 |
|---|
| Open: | 5.06 |
|---|
| Bid: | 4.20 x 500 |
|---|
| Ask: | 5.34 x 1000 |
|---|
| 1y Target Est: | 6.88 |
|---|
| Beta: | 1.77 |
|---|
| Next Earnings Date: | 31-Jul-13 |
|---|
| Day's Range: | 5.05 - 5.26 |
|---|
| 52wk Range: | 2.68 - 5.58 |
|---|
| Volume: | 316,354 |
|---|
| Avg Vol (3m): | 694,376 |
|---|
| Market Cap: | 356.95M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.34 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CERUS CORP FinancialsEDGAR Online Financials(Fri, May 10)
- 5 of Last Week's Biggest Losersat Motley Fool(Sun, May 5)
- CERUS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 3)
- Finding Innovative Drugs that are Genuinely Differentiated and Not an Incremental Improvement is the Key to Biotech Success, According to Expert Analyst Boris PeakerWall Street Transcript(Wed, May 1)
- Cerus Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- Cerus Corporation Reports First Quarter 2013 ResultsBusiness Wire(Tue, Apr 30)
- CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, Apr 30)
- Q1 2013 Cerus Corporation Earnings Release - After Market CloseCCBN(Tue, Apr 30)
- 3 Healthcare Stock Stories for Midweek Investment Wellnessat Wall St. Cheat Sheet(Wed, Apr 24)
- Cerus announces FDA agreement on modular PMA application shelltheflyonthewall.com(Wed, Apr 24)
- Cerus Announces FDA Agreement on Modular Premarket Approval (PMA) Application Submission Process for INTERCEPT PlateletsBusiness Wire(Wed, Apr 24)
- Cerus to Release First Quarter 2013 Results on April 30, 2013Business Wire(Wed, Apr 17)
- U.S. Stock Options With Biggest Changes in Implied Volatilityat Bloomberg(Tue, Apr 16)
- Traders Are Cautious Of These Illiquid Stocks With Troubling Inventory Trendsat Seeking Alpha(Tue, Apr 9)
- Swissmedic and Swiss Red Cross Present National Haemovigilance Data Showing Favourable Safety Profile for INTERCEPT-Treated Platelet ComponentsBusiness Wire(Wed, Apr 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 9.68 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.45 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
View More